报告内容：
1、报告题目: Research and Teaching in the Faculty of Pharmacy, University of Helsinki, Finland
报告人 : Professor Jouni Hirvonen, University of Helsinki
2、报告题目:Engineered Nanomedicines for Enhanced Tumor-Penetration, Prevent Cancer Recurrence, and Tissue Regeneration
报告人 : Professor Hélder A. Santos, University of Helsinki
报告时间: 2018年10月20日9:00-11:00
报告地点:生科院九楼会议室
邀请人 :杨祥良 教授/李子福 教授
报告专家简介：
Professor Jouni Hirvonen
Dr. Hirvonen is a professor of Pharmaceutical Technology in University of Helsinki since 1998 and then, promoted to vice dean and academic affairs in faculty of pharmacy, University of Helsinki in 2004. And since 2010, he was promoted further to be the Dean at the same place. Professor Hirvonen has obtained many awards and titles. He received 25 major grants which more than 7 million Eur in total from many famous institutes and leaded European Union Funded Teaching development projects (Pharmine and PHAR-QA) in 2007-2016. And also, he was appointed as the editor of Dosis (the only scientific pharmaceutical journal in Finland) from 2003 to 2010, the member of the national and European Pharmacopoeia committees (EDQM) from 2010-2016, the board member of the European Association of the Faculties in Pharmacy (EAFP) since 2012 and the President of Controlled Release Society in Nordic Chapter from 2008-2012. What’s more, Professor Hirvonen was also awarded as Young Scientist of the year 1993 in University of Kuopio, Finland, The Nagai Foundation Tokyo CRS Graduate Student in 1998 and the CRS/Eurand Grand prize on 34th Annual Meeting of the Controlled Release Society. Moreover, Professor Hirvonen is prolific in his research areas for more than 250 original research articles, review articles, book chapters and 29 supervised PhD theses have been published since 1990. His interests focus on (bio) pharmacy, pharmaceutical technology, controlled drug delivery technologies, physical pharmacy and also, surface and colloid (nano) sciences.
Professor Hélder A. Santos
Dr. Santos (D.Sc. Tech., Chem. Eng.) received his doctorate degree (2007) in Chemical Engineering from Helsinki University of Technology, Finland. Currently, an Associate Professor (tenure track) in Pharmaceutical Nanotechnology, Head of Division of Pharmaceutical Chemistry and Technology, Head of the Preclinical Drug Formulation and Analysis Group, and Director of the Doctoral Program in Drug Research at the Faculty of Pharmacy, University of Helsinki. Dr. Santos research interests include the development of nanoparticles/nanomedicines for biomedical and healthcare applications. His current work makes the bridge between engineering, pharmaceutical and medical research. His main research focus is in the use of biodegradable and biocompatible nanoporous silicon nanomaterials, polymers, the application of microfluidics technology for nanoparticle production for simultaneous controlled drug delivery, diagnostic and treatment of cancer, diabetes, and cardiovascular diseases, and further translation of these nanotechnologies into the clinic.
报告内容摘要：
Novel biomedical engineering technologies have been underlined as very promising means for the advance in medical research. Personalized medicine allows for the identification of the right therapy, reaching the right therapeutic target in the body at the right time in an efficient manner, with reduced undesired collateral effects. In this context, target nanomedicines are of great interest towards the development of personalized medicines and envisaged for their large-scale implementation. Recently, we have developed prominent biomaterials, such as porous silicon and polymer-based micro/nano-particles as potential platforms for cancer theranostics, diabetes, cardiovascular diseases and tissue engineering. All these biomaterials are promising advanced drug delivery technologies for biomedical applications. The results of the efficient surface biofunctionalization, targeting, imaging, encapsulation of drug molecules using advanced technologies, such the microfluidics technique, are presented and discussed in detail. Examples on how these materials can be used to specific targeting, cell differentiation, in vivo biofate (imaging) and intracellular targeting for different diseases (e.g., cancer, neural and cardiovascular diseases), are also presented. Overall, the recent cutting-edge advances on nanomaterials are anticipated to overcome some of the therapeutic window and clinical applicability of many drug/peptide molecules, and can also act as innovative theranostic platforms and tools for the clinic, because they offer a less invasive alternative compared to the conventional therapeutic strategies and, thereby, enhancing the expectancy and quality of life of the patients.
